FOSTER CITY, Calif.–(BUSINESS WIRE) August 22, 2023 — Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the United States Food and Drug Administration (FDA) has assigned a standard review and…Original Article
Geron Announces PDUFA Date for Imetelstat NDA in Lower Risk MDS
